Scopus Biopharma Stock Z Score
Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
Scopus |
Scopus Biopharma OTC Stock Z Score Analysis
Scopus Biopharma's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
Current Scopus Biopharma Z Score | -9.9 |
Most of Scopus Biopharma's fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Scopus Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
| |||||||
| |||||||
| |||||||
| |||||||
|
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
CompetitionBased on the company's disclosures, Scopus Biopharma has a Z Score of -9.9. This is 246.67% lower than that of the Healthcare sector and notably lower than that of the Biotechnology industry. The z score for all United States stocks is notably higher than that of the company.
Scopus Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Scopus Biopharma's direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Scopus Biopharma could also be used in its relative valuation, which is a method of valuing Scopus Biopharma by comparing valuation metrics of similar companies.Scopus Biopharma is currently under evaluation in z score category among its peers.
Scopus Fundamentals
Return On Equity | -15.6 | ||||
Return On Asset | -4.61 | ||||
Current Valuation | 1.18 M | ||||
Shares Outstanding | 21.09 M | ||||
Shares Owned By Insiders | 50.66 % | ||||
Shares Owned By Institutions | 2.15 % | ||||
Number Of Shares Shorted | 23.77 K | ||||
Price To Book | 2.42 X | ||||
EBITDA | (26.18 M) | ||||
Net Income | (26.95 M) | ||||
Cash And Equivalents | 1.16 M | ||||
Cash Per Share | 0.05 X | ||||
Total Debt | 2.54 M | ||||
Debt To Equity | 0.61 % | ||||
Current Ratio | 0.31 X | ||||
Book Value Per Share | (0.26) X | ||||
Cash Flow From Operations | (11.42 M) | ||||
Short Ratio | 0.22 X | ||||
Earnings Per Share | (1.51) X | ||||
Target Price | 12.0 | ||||
Beta | 1.16 | ||||
Market Capitalization | 2.17 M | ||||
Total Asset | 8.19 M | ||||
Z Score | -9.9 | ||||
Net Asset | 8.19 M |
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Consideration for investing in Scopus OTC Stock
If you are still planning to invest in Scopus Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Scopus Biopharma's history and understand the potential risks before investing.
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |